Bone Marrow Somatic Mutation after Genotoxic Cancer Therapy
ISBN or ISSN
Publication Date / Copyright Date
The glycophorin A (GPA) somatic mutation assay has been shown to act as cumulative biodosimeter of chemotherapy in pediatric patients, but to show no response to localized high-dose radiotherapy. These results are consistent with studies in adult populations treated with cyclophosphamide and doxorubicin or cisplatin, but inconsistent with results showing induction of somatic mutation at the GPA locus in patients treated with localized or implant radiation. The GPA assay directly measures in-vivo somatic mutation and segregation occurring by any of several molecular mechanisms implicated in oncogenesis. It has the advantage of integrating environmental and genetic factors when evaluating the long-term health effects of medical exposures. Ultimately, application of this and other intermediate biomarkers of carcinogenesis will permit individualized design and modification of therapeutic regimen and better prognostic assessment in all types of cancer.
Medical Specialties | Medicine and Health Sciences | Osteopathic Medicine and Osteopathy
Grant, Stephen G. and Bigbee, William L., "Bone Marrow Somatic Mutation after Genotoxic Cancer Therapy" (1994). Faculty Articles. 659.